hVIVO plc (LSE:HVO) said it will publish its interim results for the six months ended 30 June 2026 on 15 September.
The company will hold an analyst briefing on the same day, led by Chief Executive Yamin ‘Mo’ Khan and Chief Financial Officer Stephen Pinkerton.
hVIVO will also host a separate online presentation for investors on 15 September. The event will be available through registration and is open to existing and potential shareholders.
The presentations will accompany the company’s financial and operational update for the first half of 2026.
More about hVIVO plc
hVIVO plc is a London-listed clinical development services company specialising in human challenge clinical trials for biopharmaceutical companies.
The group operates dedicated sites and laboratories in the U.K. and Germany and provides services covering clinical and regulatory consulting, clinical trial execution, human challenge studies and laboratory activities.
hVIVO operates a quarantine facility in London for human challenge studies, while its laboratory services include virology, immunology, biobanking and sample storage.
The company’s FluCamp business maintains a specialist participant recruitment database used to support enrolment into clinical studies.
Leave a Reply